Chicago-based Diagnostic Photonics has recieved $3 million in equity venture capital funding, according to a regulatory filing.
The company’s focus is developing microscopic imaging that uses near-infrared light source technology, which is designed to allow physicians to have a better understanding of where dead tissue exists when performing surgical operations.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
According to the company, its technology “generates diffraction-corrected images of tissue microstructure by solving the mathematical equations governing the physics of light at high speed, transforming defocused images into in-focus ones.”
Diagnostic Photonics, founded in 2008 on technology pioneered at the Beckman Institute for Advanced Science and Technology at the University of Illinois, is still seeking an additional $3 million in funding. A representative was unavailable to comment on how the new funding will be used.
Photo: Screenshot via Diagnostic Photonics